Top

Published in:

Open Access 01-12-2010 | Case report

Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report

Authors: Yu Ri Seo, Se Hyung Kim, Hyun Jung Kim, Chan Kyu Kim, Seong Kyu Park, Eun Suk Koh, Dae Sik Hong

Published in: Journal of Hematology & Oncology | Issue 1/2010

Abstract

No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.

Available only for authorised users

Oosterlinck W, Solsona E, Meijden van der APM, Sylvester R, Böhle A, Rintala E, Lobel B: EAU Guidelines on Diagnosis and Treatment of Upper Urinary Tract Transitional Cell Carcinoma. European Urology. 2004, 46: 147-154. 10.1016/j.eururo.2004.04.011.CrossRefPubMed

Sternberg CN, Yagoda A, Scher HI: Methotrexate, vinblastine, doxorubicin, and cisplatin for Advanced Transitional Cell Carcinoma of the Urothelium. Efficacy and patterns of response and relapse. Cancer. 1989, 64: 2448-2458. 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7.CrossRefPubMed

Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985, 3: 1463-1470.PubMed

Roth BJ, Bajorin DF: Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). world J Urol. 1995, 153: 894-900.CrossRef

Maase von der H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: J Clin Oncol. 2000, 18: 3068-3077.PubMed

Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998, 34: 1208-1212. 10.1016/S0959-8049(98)00030-6.CrossRefPubMed

Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997, 12: 3441-3445.

Bajorin , Dodd P, Mazumdar M, Fazzari M, McCaffrey J, Scher H, Herr H, Higgins G, Boyle M: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999, 17: 3173-3181.PubMed

Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, Baselga J: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002, 95: 751-757. 10.1002/cncr.10762.CrossRefPubMed

10.

Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J: Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology. 2007, 18: 1359-1362. 10.1093/annonc/mdm160.CrossRefPubMed

11.

Dunn TA, Schmoll HJ, Granwald V, Bokemeyer V, Casper J: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs. 1997, 15: 109-114. 10.1023/A:1005800520747.CrossRefPubMed

12.

Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996, 52: 1855-1865. 10.1016/S0006-2952(97)81490-6.CrossRefPubMed

13.

Moore MJ, Winquist E, Vokes E, Hirte H, Hoving K, Stadler WM: Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol. 2003, 22: 48-52.

14.

Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM: A Phase II study of oxaliplatin in urothelial cancer. 2005, Urologic Oncology: Seminars and Original Investigations, 23: 150-154.

15.

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000, 18: 136-147.PubMed

16.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and 5-FU/leucovorin over either therapy alone in patients with progressive colorectal cancer following irinotecan and 5-FU/leucovorin: interim results of a phase III trial. J Clin Oncol. 2003, 21: 2059-2069. 10.1200/JCO.2003.11.126.CrossRefPubMed

17.

Yagoda A: Chemotherapy of urothelial tract tumors. Cancer. 1987, 60: 574-585. 10.1002/1097-0142(19870801)60:3+<574::AID-CNCR2820601524>3.0.CO;2-C.CrossRefPubMed

18.

Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ: Fluorouracil and recombinant human interferon alpha-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst. 1991, 83: 285-288. 10.1093/jnci/83.4.285.CrossRefPubMed

19.

Highley MS, Griffithsy GO, Uscinskay BM, Huddartz JB, Barberx P, Parmary MKB, Harper PG: A Phase II Trial of Continuous 5-Fluorouracil in Recurrent or Metastatic Transitional Cell Carcinoma of the Urinary Tract. Clinical Oncology. 2009, 21: 394-400. 10.1016/j.clon.2009.01.011.CrossRefPubMed

20.

Javle M, Hsueh CT: Updates in Gastrointestinal Oncology - insights from the 2008 44^th annual meeting of the American Society of Clinical Oncology. Journal of Hematology & Oncology. 2009, 2: 9-CrossRef

21.

Malavasi N, Ponti G, Depenni R, Bertolini F, Zironi S, Luppi G, Conte PF: Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. Journal of Hematology & Oncology. 2009, 2:

22.

Lorenzo GD, Autorino R, Giordano A, Giuliano M, D'Armiento M, Bianco1 AR, De Placido S: FOLFOX-4 in Pre-treated Patients with Advanced Transitional Cell Carcinoma of the Bladder. Jpn J Clin Oncol. 2004, 34: 747-750. 10.1093/jjco/hyh132.CrossRefPubMed

23.

Perabo FGE, Müller SC: New agents for treatment of advanced transitional cell carcinoma. Annals of Oncology. 2007, 18: 835-843. 10.1093/annonc/mdl331.CrossRefPubMed

Title: Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report
Authors: Yu Ri Seo
Se Hyung Kim
Hyun Jung Kim
Chan Kyu Kim
Seong Kyu Park
Eun Suk Koh
Dae Sik Hong
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2010
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-3-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Autoimmune conditions and hairy cell leukemia: an exploratory case-control study

Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology

Treatment options for patients with triple-negative breast cancer

An epidemiological investigation of leukemia incidence between 2003 and 2007 in Nanjing, China

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Keynote webinar | Spotlight on antibody–drug conjugates in cancer